Latest From Exelixis Inc.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
CEO David Meek Says Ipsen has more than $1bn for M&A use to expand its product line in oncology, neuroscience and rare diseases.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.
Roche has continued to drip-feed results from the IMmotion151 Phase III study, this time describing the magnitude of the beneficial responses observed with the first-line use of the Tecentriq-Avastin combination in patients with advanced renal cell cancer.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Exelixis Inc.
- Senior Management
Michael M Morrissey, PhD, Pres. & CEO
Christopher J Senner, EVP, CFO
Peter Lamb, PhD, EVP, Scientific Strategy & CSO
Gisela M Schwab, MD, Pres., Prod. Dev. & CMO
- Contact Info
Phone: (650) 837-7000
210 East Grand Ave.
P.O. Box 511 S. San Francisco, CA 94083-0511
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.